

Kyle A Blum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3585152/publications.pdf>

Version: 2024-02-01

24
papers

671
citations

687363

13
h-index

610901

24
g-index

26
all docs

26
docs citations

26
times ranked

999
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell sequencing links multiregional immune landscapes and tissue-resident T ^A cells in ccRCC to tumor topology and therapy efficacy. <i>Cancer Cell</i> , 2021, 39, 662-677.e6.	16.8	179
2	Sarcomatoid renal cell carcinoma: biology, natural history and management. <i>Nature Reviews Urology</i> , 2020, 17, 659-678.	3.8	76
3	JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management. <i>Modern Pathology</i> , 2019, 32, 1344-1358.	5.5	49
4	A pan-cancer analysis of PBAF complex mutations and their association with immunotherapy response. <i>Nature Communications</i> , 2020, 11, 4168.	12.8	46
5	Cytotoxic innate lymphoid cells sense cancer cell-expressed interleukin-15 to suppress human and murine malignancies. <i>Nature Immunology</i> , 2022, 23, 904-915.	14.5	39
6	Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging. <i>Journal of Urology</i> , 2018, 200, 275-282.	0.4	31
7	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. <i>Clinical Cancer Research</i> , 2020, 26, 3629-3640.	7.0	30
8	Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma. <i>European Urology Focus</i> , 2018, 4, 986-994.	3.1	29
9	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. <i>European Urology Focus</i> , 2021, 7, 381-389.	3.1	28
10	Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma. <i>European Urology Oncology</i> , 2018, 1, 364-377.	5.4	21
11	Molecular characterization of sarcomatoid clear cell renal cell carcinoma unveils new candidate oncogenic drivers. <i>Scientific Reports</i> , 2020, 10, 701.	3.3	21
12	Predicting the Impacted Ureteral Stone with Computed Tomography. <i>Urology</i> , 2019, 130, 43-47.	1.0	20
13	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. <i>European Urology Oncology</i> , 2020, 3, 47-56.	5.4	20
14	Role of lymph node dissection in renal cell cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 187-192.	1.6	14
15	A contemporary lower pole approach for complete staghorn calculi: outcomes and efficacy. <i>World Journal of Urology</i> , 2018, 36, 1461-1467.	2.2	11
16	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. <i>Urology</i> , 2020, 136, 169-175.	1.0	9
17	Comparison of Cancer Specific Outcomes following Minimally Invasive and Open Surgical Resection of Early Stage Kidney Cancer from a National Cancer Registry. <i>Journal of Urology</i> , 2020, 203, 1094-1100.	0.4	9
18	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 916-923.	1.6	8

#	ARTICLE	IF	CITATIONS
19	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. <i>Cancer Discovery</i> , 2022, 12, 2308-2329.	9.4	7
20	The association of renal cell carcinoma with gastrointestinal stromal tumors. <i>Journal of Surgical Oncology</i> , 2018, 117, 1716-1720.	1.7	6
21	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 811.e9-811.e16.	1.6	6
22	Preoperative nomogram predicting 12-year probability of metastatic renal cancer " evaluation in a contemporary cohort. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 853.e1-853.e7.	1.6	6
23	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma " An exploratory analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 791.e17-791.e24.	1.6	3
24	An evaluation of the role of tumor load in cytoreductive nephrectomy. <i>Canadian Urological Association Journal</i> , 2020, 14, E625-E630.	0.6	1